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Patient and Methods: Twenty-four patients with completely resected 
stage I-IIIA non-small lung cancer were administered 3 cycles of 
adjuvant chemotherapy consisting of carboplatin at an AUC of 4 and 
gemcitabine at dose 1000mg/m2 on day 1 and 15, in a 4-week cycle. 
Patients’ average age was 56.5 years and 96% of patients had ECOG 
performance status 0; 41.6% had pathological stage IIIA and 58.4% 
stage IB and II. Histologic tumor subtype was: 62.5% adenocarcinoma, 
33.3% squamous cell carcinoma and 4.1% large-cell undifferentiated 
carcinoma.
Results: All patients enrolled in the study received the planned 3 
cycles of adjuvant chemotherapy (compliance 100%). Myelotoxicity 
of all grades was observed in 8(33.3%) patients; grade 1-2 anemia in 
7(29%), grade 1-3 thrombocytopenia in 2(8.3%) and grade 1 leucope-
nia in 1(4.1%). G-CSF at dose 33.6miu/day s.b. was administered on 
D4-D6 and D18-D20 of each cycle. Non-hematologic toxicity consist-
ed of all grade nausea/vomiting(12.5%) and all grade diarrhea(8.3%). 
No treatment-related death was observed. The 2-year survival rate was 
87.5%, and especially for stage IIIA patients 70%. A 5-year follow-up 
is ongoing.
Conclusions: We identiﬁed a comparable efﬁcacy of adjuvant 
Carboplatin+Gemcitabine combination regimen with the one observed 
with Cisplatin-based chemotherapy regimens, however exhibiting a 
better toxicity proﬁle and a high standard of compliance. 
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Background: Combination of chemotherapy and thoracic radiation 
therapy is the best available treatment for locally advanced unresect-
able NSCLC. Results of conventional RT and CT are still not up to the 
acceptable level. We conducted a trial to compare chemotherapy given 
concurrently with twice daily external radiotherapy and conventional 
external radiotherapy alone in locally advanced NSCLC.
Methods: Fifty patients of locally advanced unresectable NSCLC were 
inducted into two arms, A & B. Twenty ﬁve patients of arm-A received 
chemotherapy with Cisplatin 75mg/m2 intravenously given starting on 
day 1 of radiation therapy for 5 courses at 3 weeks interval and vinblas-
tine 5mg/m2 given weekly for 5 courses starting on day 1 of radiation 
along with twice daily external thoracic radiation therapy. The radiation 
was given twice daily at a dose of 1.3 Gy per fraction with each frac-
tion separated by a minimum of 6 hours. A total dose of 60 Gy in 46 
fractions over 4 weeks and 3 days was delivered. Twenty ﬁve patients 
of arm-B received only conventional external radiotherapy 60Gy in 30 
fractions, 5 days a week over 6 weeks.
Results: Six weeks after the completion of treatment 67% of the 
patients in arm A showed some tumor response (27% CR; 40% PR) as 
compared to only 42% patients in the arm B. The only severe toxici-
ties observed were leucopenia (5 patients in arm A) and esophagitis, 
grade 3 (4 patients in the arm A and 3 patients in arm B). At one year 
the survival rates were 61% in arm A and 39% in the arm B. No patient 
required hospitalization due to treatment related toxicity.
Conclusion: To conclude, hyper fractionated radiotherapy and che-
motherapy regimen has promising efﬁcacy and manageable toxicity in 
unresectable advanced NSCLC.
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Background: Both local and distant failure rates are high for inoper-
able NSCLC treated by combination chemoradiation (CRT). We have 
previously reported that docetaxel (Doc) demonstrates longer G2/M 
arrest and better sub-additive effects with radiation when compared 
with paclitaxel in pre-clinical investigations. We subsequently reported 
a clinical study using pulsed low-dose paclitaxel radiosensitizing 
strategy, which yielded a 98% in-ﬁled chest tumor control rate [Clin 
Cancer Res, 9: 969-975, 2003]. With the encouraging local tumor con-
trol by pulsed taxane CRT, we conducted a phase II study using pulsed 
low-dose sensitizing Doc CRT targeting local tumor, plus one-cycle of 
induction chemotherapy (CT) of Doc/cisplatin (CP) targeting distant 
micrometastasis upfront for patients (pts) with stage III NSCLC.
Methods: Pts with inoperable stage III NSCLC were eligible. Induc-
tion CT consisted of Doc 75mg/m2 and CP 75mg/m2 on d 1 followed 
by rhG-CSF (150 ug/m2 sq on d 2 to 10). The CRT consisted of Doc 12 
mg/m2 twice/wk with daily RT, 64.8 Gy to gross tumors and 45-57.6 
Gy to subclinical disease. PK studies of Doc were performed during CT 
and during CRT in each pt. The clearance (CL), area under the plasma 
concentration versus time curve (AUC), and drug half-life (t1/2) were 
estimated.
Results: 26 pts were enrolled and 16 completed study. Overall response 
rate was 69% [50% (8/16) PR and19% (3/16) CR]. 2-year survival was 
57 %. During induction CT, primary grade (G) 3 toxicities were allergic 
reaction (10%), non-neutropenic infection (20%), nausea/vomiting 
(N/V) (10%), fatigue (10%), hypertension (5%) hyperglycemia (5%), 
dyspnea (5%) & fatigue (5%). There was no G3/4 hematologic toxicity. 
During CRT, 50% (4/8) developed grade 3 esophagitis at the initial 
twice-weekly Doc dose of 12 mg/m2. Eight subsequent pts received 
reduced Doc to 10 mg/m2 with only one grade 3 esophagitis. Other G3 
toxicities from CRT were N/V(28%), fatigue(14%), anorexia(14%), 
ﬂushing(7%), chest pain(7%), & diarrhea(7%). We observed no G3 or 4 
pneumonitis or any other G4 toxicity. Mean ± SD of Doc CL at 75 and 
10 mg/m2 was 20 ± 5 and 22 ± 10 L/h/m2, respectively. Ratio of Doc 
CL at 75 to 10 mg/m2 within a pt was 1.0 ± 0.4. Doc AUC at 75 and 10 
mg/m2 was 3,933 ± 1,028 and 566 ± 257ng/ml•h, respectively, with a 
ratio of 8.31 ± 3.84 for 75 mg/m2 to 10 mg/m2. Half-life of Doc at 75 
and 10 mg/m2 was 15.4 ± 3.7 hrs and 15.0 ± 2.2 hrs, respectively, with 
a ratio of 1.08 ± 0.15. 
Conclusions: One-cycle full-dose Doc/CP with rhG-CSF followed 
by pulsed low-dose Doc CRT is associated with promising antitumor 
activity and low hematologic toxicity. Grade 3 esophagitis was associ-
